Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average recommendation of “Buy” by the eighteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $82.31.
A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $95.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, January 15th. Jefferies Group lifted their target price on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Robert W. Baird reissued a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd.
In other Neurocrine Biosciences news, insider Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total value of $471,176.16. Following the completion of the sale, the insider now directly owns 19,436 shares of the company’s stock, valued at $1,458,477.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the sale, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Insiders have sold 189,707 shares of company stock valued at $14,975,715 in the last three months. 4.80% of the stock is owned by insiders.
Neurocrine Biosciences (NASDAQ NBIX) opened at $78.57 on Friday. The company has a market cap of $6,950.00, a price-to-earnings ratio of -35.39, a PEG ratio of 13.67 and a beta of 0.26. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences has a fifty-two week low of $39.21 and a fifty-two week high of $91.82.
COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Given Average Rating of “Buy” by Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/09/neurocrine-biosciences-inc-nbix-given-average-rating-of-buy-by-analysts.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.